今日观察！A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.

全国铁路今起实行新运行图：高铁动卧首发 京港沪港间“夕发朝至”

北京6月18日电 记者从中国国家铁路集团有限公司获悉，今日起，全国铁路实行新的列车运行图。新图以服务旅客出行需求为导向，聚焦旅客舒适度、便捷度，着力提升铁路运输服务质量，更好满足人民群众多样化出行需求。

新图共安排旅客列车5055对，其中动车组列车3948对，占比78.1%。新增开行多趟旅客列车，优化调整部分列车运行方案，进一步扩大高铁动车组覆盖范围，更好服务经济社会发展和旅客出行需求。

亮点一：京港沪港高铁动卧列车首发

今日起，北京西、上海虹桥与香港西九龙站间开行的普速直通车Z97/Z98、Z99/Z100次提质升级为北京西、上海虹桥与香港西九龙站间的高铁动卧列车D909/D910、D907/D908次，运行时速由原先的160公里/小时提高至200公里/小时，北京、上海至香港的全程旅行时间分别由24小时31分、19小时34分压缩至12小时34分、11小时14分，京港、沪港间实现夕发朝至，香港与内地间人员往来将更加便利。

亮点二：新增多趟标杆列车

全线安排停站少、速度快、旅时短的标杆列车99列，较现图增加36列，辐射20个省份，其中G311/G312次上海虹桥至北京南、G421/G422次广州南至北京南、G165/G166次西安北至北京南等多趟标杆列车运行时间进一步压缩。

亮点三：完善中西部地区列车开行结构

新图进一步完善中西部地区列车开行结构，在郑州、武汉、长沙等城市间增开标杆列车28列，进一步压缩中部地区省会城市间时空距离；首开太原至深圳动车组列车，两地间旅行时间为8小时17分，较普速旅客列车压缩27小时57分；新增乌鲁木齐至西安、银川至西安、兰州至重庆等多趟中西部地区旅客列车。

亮点四：加强中欧（亚）班列运输组织

新图加强中欧（亚）班列运输组织，精心编制中欧班列全程时刻表，新增铺画重庆、武汉、义乌、广州等与德国杜伊斯堡、波兰华沙间全程时刻表中欧班列，保障国际供应链产业链稳定畅通。

亮点五：服务保障再升级

新图坚持以旅客为中心，不断提升旅客服务水平，在部分重点方向旅客列车上配置“列车管家”、增设“爱心席”、优化“无障碍服务”等，更好满足老年人、残疾人、孕产妇等特殊群体的出行需求。

记者：陈诗文